PGEN Stock Analysis: Precigen | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 1.872m USD | 12M Return: 246.5% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 26.6M
Qual. Beats: 0
Rev. Trend: 11.0%
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Precigen (NASDAQ: PGEN) is a U.S.-based, clinical-stage biopharmaceutical company that develops gene and cell therapies targeting immuno-oncology, autoimmune disorders, and infectious diseases. The company operates two core therapeutic platforms: AdenoVerse, which uses proprietary adenoviral vectors for gene delivery of therapeutic effectors and vaccine antigens, and UltraCAR-T, which enables the manufacturing of chimeric antigen receptor T-cell therapies for cancer patients.
Precigens pipeline includes several clinical-stage candidates built on these platforms, including UltraCAR-T programs PRGN-3005 (ovarian and related cancers), PRGN-3006 (acute myeloid leukemia and high-risk myelodysplastic syndromes), and PRGN-3007 (ROR1-positive tumors), as well as AdenoVerse programs PRGN-2009 (HPV-positive solid tumors) and PRGN-2012 (recurrent respiratory papillomatosis). The company also markets UltraPorator, a proprietary electroporation device used in cell therapy manufacturing. Precigen was founded in 1998 as Intrexon Corporation, adopted its current name in February 2020, and is headquartered in Germantown, Maryland.
As a clinical-stage biotechnology company with no currently commercialized products, Precigens business model centers on advancing early- and mid-stage drug candidates through clinical trials, with funding typically derived from equity financings, partnerships, and non-dilutive sources rather than product revenue. The broader gene and cell therapy sector remains capital-intensive and heavily dependent on clinical trial outcomes and regulatory milestones to drive valuation.
- PRGN-2012 Phase 2 data in HPV-related papillomatosis expected this quarter
- Rising R&D cash burn threatens runway amid clinical-stage operations
- UltraCAR-T pipeline faces competition from approved Gilead and Bristol CAR-T therapies
| Net Income: -204.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: -1.38 > 0.02 and ΔFCF/TA -23.14 > 1.0 |
| NWC/Revenue: 255.0% < 20% (prev 1.44k%; Δ -1.19k% < -1%) |
| CFO/TA -0.83 > 3% & CFO -115.3m > Net Income -204.4m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.82 > 1.5 & < 3 |
| Outstanding Shares: last quarter (313.0m) vs 12m ago 6.50% < -2% |
| Gross Margin: 75.63% > 18% (prev -9.76%; Δ 85.39% > 0.5%) |
| Asset Turnover: 23.63% > 50% (prev 3.26%; Δ 20.37% > 0%) |
| Interest Coverage Ratio: -29.36 > 6 (EBIT TTM -198.9m / Interest Expense TTM 6.77m) |
| A: 0.58 (Total Current Assets 101.7m - Total Current Liabilities 21.1m) / Total Assets 138.6m |
| B: -16.95 (Retained Earnings -2.35b / Total Assets 138.6m) |
| C: -1.49 (EBIT TTM -198.9m / Avg Total Assets 133.7m) |
| D: 0.17 (Book Value of Equity 20.2m / Total Liabilities 118.4m) |
| Altman-Z'' = -61.25 = D |
| DSRI: 3.0 (Receivables 26.7m/1.06m, Revenue 31.6m/4.20m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.73 (AQ_t 0.14 / AQ_t-1 0.19) |
| SGI: 7.52 (Revenue 31.6m / 4.20m) |
| TATA: -0.64 (NI -204.4m - CFO -115.3m) / TA 138.6m) |
| Beneish M = 3.07 (Cap -4..+1) = D |
As of July 08, 2026, the stock is trading at USD 5.51 with a total of 7,373,814 shares traded. Over the past week, the price has changed by -6.93%, over one month by +54.34%, over three months by +33.74% and over the past year by +246.54%.
Current recommended Stop Loss: 4.80 (which is 12.9% or 2.1 ATR below the current price).
Precigen has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold PGEN.
- StrongBuy: 1
- Buy: 2
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 12.5 | 126% |
P/E Forward = 263.1579
P/S = 59.2398
P/B = 92.6735
Revenue TTM = 31.6m USD
EBIT TTM = -198.9m USD
EBITDA TTM = -195.2m USD
Long Term Debt = 93.5m USD (from longTermDebt, last quarter)
Short Term Debt = 1.07m USD (from shortTermDebt, last quarter)
Debt = 103.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 4.73m
Net Debt = 46.7m USD (calculated: Debt 103.0m - CCE 56.2m)
Enterprise Value = 1.92b USD (1.87b + Debt 103.0m - CCE 56.2m)
Interest Coverage Ratio = -29.36 (Ebit TTM -198.9m / Interest Expense TTM 6.77m)
EV/FCF = -10.00x (Enterprise Value 1.92b / FCF TTM -191.8m)
FCF Yield = -10.00% (FCF TTM -191.8m / Enterprise Value 1.92b)
FCF Margin = -607.0% (FCF TTM -191.8m / Revenue TTM 31.6m)
Net Margin = -647.0% (Net Income TTM -204.4m / Revenue TTM 31.6m)
Gross Margin = 75.63% ((Revenue TTM 31.6m - Cost of Revenue TTM 7.70m) / Revenue TTM)
Gross Margin QoQ = 87.63% (prev 58.07%)
Tobins Q-Ratio = 13.84 (Enterprise Value 1.92b / Total Assets 138.6m)
Interest Expense / Debt = 6.58% (Interest Expense 6.77m / Debt 103.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -157.1m (EBIT -198.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.29 (Total Current Assets 101.7m / Total Current Liabilities 23.7m)
Debt / Equity = 5.09 (Debt 103.0m / totalStockholderEquity, last quarter 20.2m)
Debt / EBITDA = -0.24 (negative EBITDA) (Net Debt 46.7m / EBITDA -195.2m)
Debt / FCF = -0.24 (negative FCF - burning cash) (Net Debt 46.7m / FCF TTM -191.8m)
Total Stockholder Equity = 11.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -152.9% (out of range, set to none)
RoE = -1.77k% (out of range, set to none) (Net Income TTM -204.4m / Total Stockholder Equity 11.6m)
RoCE = -189.2% (out of range, set to none) (EBIT -198.9m / Capital Employed (Equity 11.6m + L.T.Debt 93.5m))
RoIC = -134.3% (out of range, set to none) (NOPAT -157.1m / Invested Capital 117.0m)
WACC = 6.23% (E(1.87b)/V(1.97b) * Re(6.29%) + D(103.0m)/V(1.97b) * Rd(6.58%) * (1-Tc(0.21)))
Discount Rate = 6.29% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.75 | Cagr: 10.71%
[DCF] Fair Price = unknown (Cash Flow -191.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.06 | # QB: 0
Revenue Correlation: 11.03 | Revenue CAGR: 8.74% | SUE: 1.57 | # QB: 1
EPS current Quarter (2026-06-30): EPS=-0.01 | Chg30d=N/A | Revisions=+25% | Analysts=3
EPS next Quarter (2026-09-30): EPS=-0.00 | Chg30d=N/A | Revisions=+40% | Analysts=3
EPS current Year (2026-12-31): EPS=-0.03 | Chg30d=+70.00% | Revisions=+40% | GrowthEPS=+97.8% | GrowthRev=+1184.9%
EPS next Year (2027-12-31): EPS=0.20 | Chg30d=+263.64% | Revisions=+40% | GrowthEPS=+766.7% | GrowthRev=+84.0%
[Analyst] Revisions Ratio: +70% (up=7, down=0)